Mary Flack

2.2k citations
23 papers · 1.8k · 2 hit papers · h-index 11

Impact in

  • Immunology top 1%
    • Psoriasis: Treatment and Pathogenesis
    • Immunotherapy and Immune Responses
    • Dermatology and Skin Diseases
    • Acne and Rosacea Treatments and Effects

Papers in

Mary Flack

22 papers receiving 1.7k citations

Mary Flack's Hit Papers

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials 2018 · 538 citations
5380+3+6Years since publication100200300400500

Peers

Mary Flack
Comparison fields: 5 of 57
  • Immunology 1.3k
  • Dermatology 106
  • Rheumatology 130
  • Genetics 137
  • Pharmaceutical Science 28
Replace Juul M. P. A. van den Reek with:
Juul M. P. A. van den Reek Netherlands
Robert M. Day United States
Ziqian Geng United States
Paolo Dapavo Italy
Luke Peterson United States
Francesco Loconsole Italy
Gaia Gallo United States
Vimal H. Prajapati Canada
Floris C. Loeff Netherlands
Anja B. Geldhof Belgium
Mary Flack relative to Juul M. P. A. van den Reek Netherlands Juul M. P. A. van den Reek's profile →
Citations per field
00.5×2×2.9×
Juul M. P. A. van den Reek · 1×
Citations per year

Countries citing papers authored by Mary Flack

Since Specialization
Citations

This map shows the geographic impact of Mary Flack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Flack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Flack more than expected).

Fields of papers citing papers by Mary Flack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Flack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Flack. The network helps show where Mary Flack may publish in the future.

Co-authors

The 25 scholars most cited alongside Mary Flack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary Flack Line = papers co-authored together Mary Flack links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Hit paper breakdown →
2018538
2
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Hit paper breakdown →
2017443
3 2019252
4 2020170
5 201984
6 201168
7 201863
8 202157
9 200122
10 200118
11 202218
12
EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
201811
13 202310
14 20219
15 20205
16 20235
17 20254
18 20212
19
Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis
20081
20 20211

About Mary Flack

Mary Flack is a scholar working on Immunology, Pathology and Forensic Medicine, Dermatology, Genetics and Pharmacology, having authored 23 papers that have together received 1.8k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (14 papers), Systemic Sclerosis and Related Diseases (3 papers), Chronic Lymphocytic Leukemia Research (1 paper), Pharmacogenetics and Drug Metabolism (1 paper), Reproductive Health and Contraception (1 paper), Influenza Virus Research Studies (1 paper), Acne and Rosacea Treatments and Effects (1 paper) and Herpesvirus Infections and Treatments (1 paper). The work is most often cited by research in Immunology (1.3k citations), Dermatology (106 citations), Rheumatology (130 citations), Genetics (137 citations) and Pharmaceutical Science (28 citations). Mary Flack has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Kim Alexander Papp, Andrew Blauvelt, Melinda Gooderham, Howard L. Sofen, Elizabeth H. Z. Thompson, Yihua Gu, James G. Krueger, Ziqian Geng, Joaquin M. Valdes and Mamitaro Ohtsuki. Their work appears in journals such as The Lancet, Journal of the American Academy of Dermatology, Journal of Scleroderma and Related Disorders, Dermatology and Therapy and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact